Maryland Oncology Hematology

🎉 Maryland Oncology Hematology is proud to welcome Dr. Ahmad Cheema to our Frederick & Mt. Airy offices. Dr. Cheema is a board‑certified, fellowship‑trained medical oncologist and hematologist. He completed his medical degree at the Services Institute of Medical Sciences in Pakistan, followed by Internal Medicine residency at the Icahn School of Medicine at Mount Sinai/St. Luke’s–Roosevelt Hospital Center, and a Hematology/Oncology fellowship at West Virginia University. He provides comprehensive, evidence‑based care for patients with a wide range of cancers and blood disorders. Dr. Cheema is dedicated to individualized treatment, compassionate communication, and collaborative, multidisciplinary care. Please join us in welcoming Dr. Cheema to Maryland Oncology Hematology! https://lnkd.in/ezrZp4rs

Welcome Dr. Jennifer Vaz to Maryland Oncology Hematology! We’re thrilled to have Dr. Vaz join our team of experts at our Rockville office. She is a board-certified gynecologic oncologist with extensive experience treating ovarian, uterine, cervical, and other gynecologic cancers, as well as complex benign conditions. Dr. Vaz completed her fellowship in gynecologic oncology at the Medical College of Georgia and previously served as an assistant professor at George Washington University. Her research has been published in leading medical journals, and she is an active member of several professional organizations, including the Society of Gynecologic Oncology. She was also recognized by her peers as a Washingtonian Top Doc for 2025. Learn more: https://lnkd.in/evNjJA4w

Welcome Dr. Mark Goldstein to Maryland Oncology Hematology! We’re excited to have Dr. Goldstein join the team at our Bethesda office. He is board-certified in medical oncology, hematology, and internal medicine, with expertise in prostate, lung, and colorectal cancers, as well as myeloma and lymphoma. Dr. Goldstein brings extensive experience in clinical research, having served as principal investigator in over 20 trials. He currently serves as President of the Maryland DC Society of Clinical Oncology and is passionate about advancing cancer care and survivorship. https://lnkd.in/eWBAbwAx

Maryland Oncology Hematology is proud to welcome Dr. Paul Bannen (Olney) and Dr. Fred Smith (Chevy Chase) and their amazing staff to the MOH family. Both physicians are bringing their well-established practices into MOH, enhancing our ability to provide exceptional, community-based cancer care. We’re honored to have them join our team and look forward to continuing their legacy of compassionate, expert care.

Maryland Oncology Hematology is proud to announce the addition of a fourth LINAC machine—the Halcyon—to our Radiation Oncology program! This cutting-edge technology enhances our ability to deliver high-quality care and significantly increases patient access to treatment. The Halcyon system is designed for speed, precision, and comfort, helping us continue our commitment to compassionate, state-of-the-art cancer care. www.MarylandOncology.com

We were honored to welcome Representative Sarah Elfreth to our Annapolis office at Maryland Oncology Hematology! Her visit highlighted the power of community-based cancer care and the importance of delivering cutting-edge treatment close to home. From advanced technologies to compassionate support, we're proud to be setting the standard for oncology and hematology care in Maryland. Thank you, Representative Elfreth, for your commitment to accessible, high-quality healthcare! 💙 https://lnkd.in/eFMAmEE

Change Makers: On May 20, Maryland Oncology Hematology (MOH) attended a bill signing ceremony at the Maryland State Capitol. During the ceremony, Maryland Governor Wes Moore signed HB 1243 and SB 975 into law, which will permit cancer patients to access specialty drugs from community oncology practices and limit interference from pharmacy benefit managers (PBMs).    The bill signing culminates years of advocacy from physicians at MOH, who have worked closely with The US Oncology Network’s government relations team to hold meetings with lawmakers and provide testimony in front of key committees. This spring, Dr. Kash Firozvi testified in support of the bill, describing the benefits of medically integrated dispensing for patients, including enhanced communication between patient and provider, improved adherence, reduced drug waste, and lower costs. “Patients deserve the freedom to choose their providers and make decisions that align with their best interests,” Dr. Firozvi said. https://lnkd.in/eJFKzjB